This case is accelerated study Myelin Repair Foundation collaboration model for drug discovery. It highlights the problem of creating a multi-disciplinary and multi-institutional research collaboration, which is trying to create for the treatment of multiple sclerosis on the basis of a new scientific approach. The case provides detailed information about how the norms of scientific research and intellectual property should have been updated to enable collaboration. The current dilemma facing the CEO and chief operating officer of the fund is to establish strategic priorities for research, so that the treatment of MS may be ready in the next ten years. Strategic decisions must take into account the complexity of the drug, the uncertainty of commercial partners interested in therapeutic approach and limit donors to raise funds on the basis of the medium.
To enhance their effectiveness, color cases should be printed in color. "Hide
by Karim R. Lakhani, Paul R Carlile Source: Harvard Business School 19 pages. Publication Date: March 1, 2010. Prod. #: 610074-PDF-ENG
Related Case Solutions & Analyses:
ARCOR Groups Internationalization and the ARCOR Foundation in Brazil
Managing Collaboration: Improving Team Effectiveness through a Network Perspective
Bloemenveiling Aalsmeer
Warnaco Group Inc. (A)
Treasure Trophy Company
Barrick Gold: Eliminating the Gold Hedging Strategy
Introduction to the Canadian Income Tax System (Revised)
BCE Inc.: Bondholders Versus Shareholders Supreme Court Showdown?
Innovation at the Treasury: Treasury Inflation-Protection Securities (A)
First American Bank: Credit Default Swaps
